What is claimed is:

1. A chimeric protein comprising:

a) a recombinase, a transcription factor or nuclease; and

b) a transcription activator-like effector (TALE) protein,

wherein the TALE protein has an N-terminal domain (NTD) comprising an amino acid sequence in the N_{-1} hairpin VGKQWSGARAL except for one or more mutations therein selected from: Q is Y, Q is S, Q is R, W is G, W is deleted, S is R, S is H, S is A, S is N, and S is T.

2. The chimeric protein of claim 1, wherein the TALE protein is truncated.

3. The chimeric protein of claim 2, wherein the TALE protein comprises a C-terminal or N-terminal truncation.

4. The chimeric protein of claim 3, wherein the TALE protein comprises a C-terminal truncation.

5. The chimeric protein of claim 1, wherein the TALE protein is selected from the group consisting of: AvrXa7, Tallc, and PthXol.

6. The chimeric protein of claim 1, wherein the TALE protein comprises an amino acid sequence as set forth in SEQ ID NO: 2.

7. The chimeric protein of claim 6, wherein the TALE protein comprises a C-terminal truncation.

8. A nucleic acid molecule encoding the chimeric protein of any one of claims 1-7.

9. An expression cassette comprising the nucleic acid molecule of claim 8.

10. A vector comprising the expression cassette of claim 9.

11. A host cell transformed or transfected with the nucleic acid molecule of claim 8, the expression cassette of claim 9 or the vector of claim 10.

12. A polypeptide comprising a *Xanthomonus* derived transcription activator-like effector (TALE) protein, the TALE protein having an N-terminal domain (NTD) comprising an amino acid sequence in the N_{-1} hairpin as set forth in SEQ ID NO: 3 (VGKQWSGARAL) except for one or more mutations selected from: Q is Y, Q is S, Q is R, W is G, W is deleted, S is R, S is H, S is A, S is N, and S is T.

13. The polypeptide of claim 12, wherein the NTD comprises an amino acid sequence selected from: VGKYRGARAL (SEQ ID NO: 4), VGKSRSGARAL (SEQ ID NO: 5), VGKYHGARAL (SEQ ID NO: 6), and VGKRGAGARAL (SEQ ID NO: 7).

14. A polypeptide comprising a *Ralstonia* derived transcription activator-like effector (TALE) protein, the TALE protein having an N-terminal domain (NTD) comprising an amino acid sequence in the N_{-1} hairpin as set forth in SEQ ID NO: 8 ($IVDIAR_1QR_2SGDLA$) except for one or more mutations selected from: R_1 is K, Q is Y, Q is S, Q is R, R_2 is W, R_2 is G, R_2 is deleted, S is R, S is H, S is A, S is N, and S is T.

15. The polypeptide of claim 14, wherein the NTD comprises an amino acid sequence selected from: IVDIARQWSGDLA (SEQ ID NO: 9), IVDIARYRGDLA (SEQ ID NO: 10), IVDIARSRSGDLA (SEQ ID NO: 11), IVDIARYHGDLA (SEQ ID NO: 12), and IVDIARRGAGDLA (SEQ ID NO: 13).

16. The polypeptide of any one of claims 12-15 further comprising a recombinase domain or a nuclease domain.

17. The polypeptide of claim 12 or 13, wherein the TALE protein is derived from AvrXa7, Tal1c, or PthXo1.

18. The polypeptide of claim 12 or 13, wherein the TALE protein comprises a synthetic RVD domain.

19. The polypeptide of claim 18, wherein the TALE protein comprises a C-terminal truncation and/or a N-terminal truncation.

20. The polypeptide of claim 18, wherein the TALE protein is derived from AvrXa7, and is truncated at amino acid residue 28, 74, 87, 92, 95, 120, 124, 128, 129, 147 or 150.

21. The polypeptide of claim 16, wherein the recombinase is selected from the group consisting of Gin, Hin, Tn3, Sin, Beta, Pin. Min, Din, and Cin and muteins of Gin, muteins of Hin, muteins of Sin, muteins of Beta, muteins of Pin, muteins of Min, muteins of Din, muteins of Cin, muteins of Tn3.

22. The polypeptide of claim 16 or 21, wherein the recombinase is Gin.

23. The polypeptide of claim 16 or 21, wherein the recombinase is Gin and the TALE protein is AvrXa7.

24. A method for site-specific recombination, the method comprising:

a) providing a DNA sequence comprising at least two binding sites for specifically interacting with the chimeric protein of claim 1 or the polypeptide of claim 12 or claim 14; and

b) reacting the DNA sequence with the chimeric protein or the polypeptide,

wherein the chimeric protein or the polypeptide catalyzes a site-specific recombination event in which both strands of the DNA sequence are cleaved between the two sites specifically interacting with the chimeric protein or the polypeptide.

25. The method of claim 24, wherein the site-specific recombination event is an inversion.

26. The method of claim 24, wherein the chimeric protein or the polypeptide catalyzes site-specific integration.

27. The method of claim 25, wherein the chimeric protein comprises a nuclease domain.

28. Use of a composition comprising a nucleic acid molecule encoding the chimeric protein of claim 1 or the polypeptide of claim 12 or claim 14, in the manufacture of a medicament for the treatment of a subject requiring gene therapy wherein upon expression of the nucleic acid molecule, a gene present in the genome of the subject is specifically removed or inactivated.

29. The use of claim 28, whereby in addition to the medicament, a nucleic acid molecule comprising a functional replacement of the gene is also to be administered.

30. A nucleic acid molecule encoding a polypeptide comprising a *Xanthomonas* derived transcription activator-like effector (TALE) protein and a recombinase domain or a nuclease domain, the TALE protein having an N-terminal domain (NTD) comprising an amino acid sequence in the N_{-1} hairpin as set forth in SEQ ID NO: 3 (VGKQWSGARAL) except for one or more mutations selected from: Q is Y, Q is S, Q is R, W is G, W is deleted, S is R, S is H, S is A, S is N, and S is T.

31. The nucleic acid molecule of claim 30, wherein the NTD comprises an amino acid sequence selected from: VGKYRGARAL (SEQ ID NO: 4), VGKSRSGARAL (SEQ ID NO: 5), VGKYHGARAL (SEQ ID NO: 6), and VGKRGAGARAL (SEQ ID NO: 7).

32. A nucleic acid molecule encoding a polypeptide comprising a *Ralstonia* derived transcription activator-like effector (TALE) protein and a recombinase domain or a nuclease domain, the TALE protein having an N-terminal domain (NTD) comprising an amino acid sequence in the N_{-1} hairpin as set forth in SEQ ID NO: 8

(IVDIAR$_1$QR$_2$SGDLA) except for one or more mutations selected from: R$_1$ is K, Q is Y, Q is S, Q is R, R$_2$ is W, R$_2$ is G, R$_2$ is deleted, S is R, S is H, S is A, S is N, and S is T.

33. The nucleic acid molecule of claim 32, wherein the NTD comprises an amino acid sequence selected from: IVDIARQWSGDLA (SEQ ID NO: 9), IVDIARYRGDLA (SEQ ID NO: 10), IVDIARSRSGDLA (SEQ ID NO: 11), IVDIARYHGDLA (SEQ ID NO: 12), and IVDIARRGAGDLA (SEQ ID NO: 13).

34. The nucleic acid molecule of claim 30 or 31, wherein the TALE protein is derived from AvrXa7, Tal1c, or PthXo1.

35. The nucleic acid molecule of claim 30 or 31, wherein the TALE protein comprises a synthetic RVD domain.

36. The nucleic acid molecule of claim 35, wherein the TALE protein comprises a C-terminal truncation and/or a N-terminal truncation.

37. The nucleic acid molecule of claim 35, wherein the TALE protein is derived from AvrXa7, and is truncated at amino acid residue 28, 74, 87, 92, 95, 120, 124, 128, 129, 147 or 150.

38. The nucleic acid molecule of claim 30 or 32, wherein the recombinase is selected from the group consisting of Gin, Hin, Tn3, Sin, Beta, Pin. Min, Din, and Cin and muteins of Gin, muteins of Hin, muteins of Sin, muteins of Beta, muteins of Pin, muteins of Min, muteins of Din, muteins of Cin, muteins of Tn3.

39. The nucleic acid molecule of any one of claims 30, 32 and 38, wherein the recombinase is Gin.

40. The nucleic acid molecule of any one of claims 30, 32 and 38, wherein the recombinase is Gin and the TALE protein is AvrXa7.

41. An expression cassette comprising the nucleic acid molecule of any one of claims 30-40.

42. A vector comprising the nucleic acid molecule of any one of claims 30-40.

43. A host cell transformed or transfected with the nucleic acid molecule of any one of claims 30-40, the expression cassette of claim 41, or the vector of claim 42.

44. A composition comprising a nucleic acid molecule encoding the chimeric protein of claim 1 or the polypeptide of claim 12 or claim 14, for use in gene therapy of a subject, wherein upon expression of the nucleic acid molecule, a gene present in the genome of the subject is specifically removed or inactivated.